Merck & Co., Inc. (NYSE:MRK) is one of the best medical research stocks to buy according to hedge funds. Merck & Co., Inc.

A companion diagnostic test was simultaneously approved to identify eligible patients whose tumors express PD-L1 with a combined positive score of 1 or higher.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ ...

The FDA approved pembrolizumab (Keytruda) plus paclitaxel for recurrent ovarian cancers that express PD-L1, the agency ...

New findings have reignited hope and purpose for Avastin, says expert. January 25, 2011— -- Taking Avastin before breast cancer surgery could significantly shrink tumors and reduce the chance of ...

Adding Imfinzi and Avastin to transarterial chemoembolization led to a 23% reduction in the risk of progression or death in patients with liver cancer. Patients with unresectable hepatocellular ...

June 3, 2012 (Chicago, Illinois) — A new study has confirmed that continuing bevacizumab (Avastin) treatment beyond first progression, while modifying chemotherapy, can be beneficial for patients with ...

September 10, 2009 — There are now published data from a phase 2 multicenter trial on the effectiveness of bevacizumab (Avastin, Genentech) in patients with glioblastoma who have progressed despite ...

Merck & Co., Inc. (NYSE:MRK) is one of the best medical research stocks to buy according to hedge funds. Merck & Co., Inc. (NYSE:MRK) announced on February 11 the FDA approval of KEYTRUDA® and ...